The emergence of neoadjuvant immunotherapy and neoadjuvant immunotherapy combined with chemotherapy has further elevated the status of neoadjuvant therapy in the treatment of gastric cancer. These new approaches have shown potential in improving the pathologic complete response rate and patient survival rate,providing more treatment options for patients with locally advanced gastric cancer. However,the application of neoadjuvant immunotherapy in gastric cancer still faces some challenges. On the one hand,only a portion of patients can benefit from immunotherapy,and how to accurately screen this group of patients is currently the focus of research. On the other hand,adverse reactions related to immunotherapy also require attention and proper management,such as the occurrence of immune related adverse reactions that may affect patients' quality of life and treatment compliance. Meanwhile,the new adjuvant immunotherapy has brought new challenges to the traditional concept of radical surgery. Such as changes in surgical methods, scope of lymph node dissection, etc. Therefore, in the future, it is necessary to further explore biomarkers that can predict the efficacy of immunotherapy, screen potential beneficiaries, and optimize treatment plans to improve the effectiveness and safety of immunotherapy, in order to achieve the maximum value of neoadjuvant immunotherapy in the treatment of locally advanced gastric cancer.

Objective:To investigate the impact of neoadjuvant immunotherapy combined with chemotherapy on the safety and efficacy of radical resection in patients with cT3-4NxM0 gastric cancer.Methods:A retrospective cohort study method was used. The clinicopathological data of 515 patients who underwent radical gastrectomy after neoadjuvant treatment at Second Department of Gastric Surgery,Fudan University Shanghai Cancer Center and Department of Gastric Surgery,Zhangzhou Hospital Affiliated to Fujian Medical University from January 2020 to June 2023 were collected. Among them,379 patients received neoadjuvant chemotherapy alone(chemotherapy group),and 136 patients received neoadjuvant immunotherapy combined with chemotherapy(immunotherapy group). There were 382 males and 133 females,with an age of (58.4±10.9)years(range:26 to 85 years). To reduce the influence of potential confounding factors,a 1∶1 propensity score matching method was adopted,and the clamp value was 0.02. The peri-operative safety,imaging and postoperative pathological tumor regression,and prognosis were compared by independent sample t-test, Mann-Whitney U test, χ 2 test or Fisher exact probability method between the two groups. The Kaplan-Meier method was used to draw survival curves, and the differences between groups were compared by Log-rank test. Results:After matching, there were 101 patients in each of the chemotherapy group and the immunotherapy group. The baseline data of the patients in the two groups were evenly distributed (all P>0.05). According to the RECIST 1.1 criteria, the complete response rate (11.9% (12/101) vs. 4.0% (4/101)), partial response rate(68.3%(69/101) vs. 53.4%(54/101)), stable disease rate (17.8%(18/101) vs. 39.6%(40/101)) and disease progression rate (2.0%(2/101) vs. 3.0%(3/101)) between the immunotherapy group and the chemotherapy group were no statistical defferences ( χ2=14.374, P=0.002), and objective response rate (80.2%(81/101) vs. 57.4%(58/101), χ2=12.203, P<0.01) in the immunotherapy group was higher than that in the chemotherapy group. The results of postoperative pathological examination showed that the immunotherapy group had a higher complete response rate (16.8%(17/101) vs. 6.9% (7/101), χ2=4.728, P=0.030) and major pathological response rate (42.6%(43/101) vs. 23.8% (24/101), χ2=8.062, P=0.005). For the two groups, the operation time (175.0(76.0)minutes vs. 160.0 (30.0)minutes, Z=-0.059, P=0.953), intraoperative blood loss (110.0 (150.0)ml vs. 100.0 (120.0)ml, Z=-0.370, P=0.712), overall incidence of postoperative complications (20.8%(21/101) vs. 18.8%(19/101), χ2=0.125, P=0.724) and incidence of severe complications (5.0%(5/101) vs. 3.0%(3/101), χ2=0.130, P=0.718) were comparable. The median follow-up time of all patients was 46 months(range: 19 to 61 months). The 3-year overall survival rate (63.2% vs. 54.4%, P=0.035) and progression-free survival rate (59.1% vs. 45.6%, P=0.022) of the immunotherapy group were higher than those of the chemotherapy group. Meanwhile, there were no statistically significant differences in the incidence of neoadjuvant-treatment-related adverse events (48.5%(49/101) vs. 40.6% (41/101), χ2=1.283, P=0.411) and the incidence of severe adverse reactions of grade 3 or above (13.9% (14/101) vs. 10.9% (11/101), χ2=0.257, P=0.522) between the two groups. Conclusion:Neoadjuvant immunotherapy combined with chemotherapy can significantly improve the imaging and postoperative pathological tumor response rates and 3-year survival rate of patients with locally advanced gastric cancer,without increasing the incidence of postoperative complications and neoadjuvant treatment-related adverse event.

Objective:To explore the prognosis after radical resection for stage Ⅰ gastric cancer and the application value of adjuvant chemotherapy.Methods:The retrospective cohort study was conducted. The clinicopathological data of 3 353 patients with stage Ⅰ gastric cancer who were admitted to Fudan University Shanghai Cancer Center from January 2000 to December 2022 were collected. There were 2 369 males and 984 females, aged 60(range, 21-91) years. All patients underwent radical R 0 resection. Observation indicators: (1) clinicopathological characteristics of patients; (2) influencing factors for postoperative prognosis of patients; (3) prognostic analysis of patients; (4) construction and validation of a predictive model for the efficacy of postoperative adjuvant chemotherapy. Comparison of count data between groups was conducted using the chi-square test. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model. The Kaplan-Meier method was used to calculate survival rates and draw survival curves, and the Log-rank test was used for survival analysis. Based on the multivariate analysis result, a nomogram prediction model was constructed to predict survival benefit. Results:(1) Clinicopatho-logical characteristics of patients. The highly, moderately, and poorly differentiated tumors were observed in 16, 234, 396 cases of 646 patients aged <50 years and 279, 1 617, 811 cases of 2 707 pati-ents aged ≥50 years, respectively, showing a significant difference in degree of tumor differentiation between them ( P<0.05). For 297 patients in stage T1N1M0, cases aged <50 years and ≥50 years were 71 and 226, cases of males and females were 184 and 113, cases with negative and positive vascular invasion were 37 and 260, cases with negative and positive nerve invasion were 275 and 22, cases without and with postoperative adjuvant chemotherapy were 222 and 75, respectively. The above indicators for 678 patients in stage T2N0M0 105, 573, 533, 145, 517, 161, 526, 152, 563, 115, respectively. There were significant differences in the above indicators between the two groups ( P<0.05). (2) Influencing factors for postoperative prognosis of patients. Results of multivariate analysis showed that age ≥50 years, stage T2, moderately differentiated tumor, the number of lymph nodes dissected <16, positive vascular invasion, carcinoembryonic antigen (CEA) ≥5 μg/L, and CA19-9 ≥37 U/mL were independent risk factors for disease-free survival (DFS) after surgery for stage Ⅰ gastric cancer ( hazard ratio=4.600, 1.555, 1.835, 1.362, 1.451, 1.571, 2.134, 95% confidence interval as 2.806-7.541, 1.205-2.006, 1.016-3.314, 1.059-1.753, 1.057-1.993, 1.100-2.243, 1.257-3.625, P<0.05). Age ≥50 years, stage T2, the number of lymph nodes dissected <16, positive vascular invasion, CEA ≥5 μg/L, and CA19-9 ≥37 U/mL were independent risk factors for overall survival (OS) after surgery for stage Ⅰ gastric cancer ( hazard ratio=5.208, 1.597, 1.373, 1.520, 1.464, 2.356, 95% confidence interval as 3.028-8.955, 1.231-2.072, 1.060-1.777, 1.099-2.104, 1.004-2.134, 1.385-4.009, P<0.05). Postoperative adjuvant chemotherapy was an independent protective factor for both DFS and OS after surgery for stage I gastric cancer ( hazard ratio=0.361 0.297, 95% confidence interval as 0.177-0.736, 0.131-0.674, P<0.05). (3) Prognostic analysis of patients. According to the results of multi-variate analysis, among 3 353 patients, there were significant differences in 5-year DFS rate and 10-year OS rate between patients aged <50 years and ≥50 years ( P<0.05). There were significant differences in 5-year DFS rate and 10-year OS rate among patients in TNM stage ⅠA and ⅠB ( P<0.05). There were significant differences in 5-year DFS rate and 10-year OS rate among patients in stage T1N0M0, T1N1M0, T2N0M0 ( P<0.05). There were significant differences in 5-year DFS rate and 10-year OS rate among patients with the highly, moderately, and poorly differentiated tumors ( P<0.05). There were significant differences in 5-year DFS rate and 10-year OS rate among patients with the number of lymph lodes dissected <16 and ≥16 ( P<0.05). There were significant differences in 5-year DFS rate and 10-year OS rate between patients with negative and positive vascular invasion ( P<0.05). There were significant differences in 5-year DFS rate and 10-year OS rate between patients with and without postoperative adjuvant chemotherapy ( P<0.05), among patients in stage T1N0M0, T1N1M0, T2N0M0 who received no postoperative adjuvant chemotherapy ( P<0.05). For patients in stage T1N1M0, there was no significant difference in 5-year DFS rate and 10-year OS rate between patients with and without postoperative adjuvant chemotherapy ( P>0.05).Results of stratified analysis showed that for patients aged ≥ 50 years, there were significant differences in 5-year DFS rate and 10-year OS rate between patients with and without postoperative adjuvant chemotherapy ( P<0.05). For patients in stage T2N0M0, there were significant differences in 5-year DFS rate and 10-year OS rate between patients with and without postoperative adjuvant chemotherapy ( P<0.05). For patients with positive vascular invasion, there were significant differences in 5-year DFS rate and 10-year OS rate between patients with and without postoperative adjuvant chemotherapy ( P<0.05). (4) Construction and validation of a predictive model for the efficacy of adjuvant chemotherapy. A nomogram predictive model was constructed based on the multivariate analysis results of OS and used for calculating net benefits and distribution. Among the 3 096 patients without postoperative adjuvant chemotherapy, 1 009 cases had a predicted net benefit of >5%-10%, and 250 patients had a predicted net benefit >10%. The predicted survival analysis further verified that the predicted benefit of adjuvant chemotherapy was consistent with the prognosis of patients. Conclusions:Patients with age ≥50 years, stage T2 tumors, moderately differentiated tumor, the number of lymph nodes dissected <16, positive vascular invasion have worse survival prognosis postoperative. Postoperative adjuvant chemotherapy provides better prognosis in high-risk patients. Patients in stage T1N1M0 have lower recurrence and survival risks, of whom with 1 metastatic lymph node is more suitable for follow-up rather than postoperative adjuvant chemotherapy.

Objective:To construct a nomogram prediction model for the malignant risk of breast lesions based on quantitative multimodal ultrasound features and clinical indicators，and to explore its clinical application value.Methods:A total of 430 patients with breast diseases（473 lesions）confirmed by pathological examination at Kunshan Traditional Chinese Medicine Hospital from August 2018 to December 2023 were retrospectively analyzed in the study. All the patients underwent routine handheld ultrasound（HHUS），automated breast volume scanning（ABVS）and ultrasound elastography（UE）examinations before biopsy or surgery. Four hundred and seventy-three breast lesions were randomly divided into training set（ n=331）and validation set（ n=142）at a ratio of 7∶3. The ABVS ultrasound features of 331 lesions in the training set were analyzed to identify the risk features of malignant breast lesions. Based on the weight of the regression coefficients β，the ABVS risk features were assigned quantitative scores for each lesion. Using pathology results as the gold standard，ROC curves were plotted to compare the diagnostic efficacy of ABVS quantitative scoring and HHUS in the training set. The variable with higher efficacy was selected for inclusion in the multivariable logistic regression analysis. Based on the identified independent predictive factors，a nomogram was constructed to quantify the malignancy risk of breast lesions. The nomogram was evaluated and validated using the area under the ROC curve（AUC），calibration curve and clinical decision curve analysis（DCA）. Results:The AUC for ABVS quantitative scoring and HHUS in distinguishing benign and malignant breast lesions were 0.941 and 0.903，respectively，with a statistically significant difference（ Z=2.081， P=0.037）. Multivariate Logistic regression analysis showed that age，ABVS quantitative score and elasticity score were independent predictors for the identification of benign and malignant breast lesions（all P<0.05）. A nomogram was constructed based on the aforementioned independent predictive factors. The AUC for the nomogram were 0.968 in the training set and 0.943 in the validation set，indicating good discrimination. The calibration curve indicated that the predicted probabilities from the nomogram were in good agreement with the actual outcomes. DCA indicated strong clinical applicability of the nomogram. Conclusions:The nomogram based on ABVS quantitative scores，elasticity scores，and age demonstrates high diagnostic value，providing a novel method for preoperative assessment of the malignancy risk of breast lesions.

Objective To analyze the risk factors of neurogenic bladder dysfunction(NB)in patients with spinal cord injury,and establish a risk prediction model of NB in patients with spinal cord injury by decision tree algorithm.Method Clinical data of 176 patients with spinal cord injury admitted from April 2022 to July 2024 were retrospectively analyzed.Patients with spinal cord injury were divided into disorder group and non-disorder group according to whether they were complicated by NB.Multivariate Logistic regression analysis was used to screen the risk factors of NB.Modeler software was used to construct the decision tree model of spinal cord injury patients with concurrent NB,and the 5-fold cross-validation method was used to internally verify the model,and the prediction efficiency of the model was compared.Results Among 176 patients with spinal cord injury,42 patients had concurrent NB,the incidence of NB was 23.86%.Logistic regression analysis showed that the level of spinal cord injury(T10—L2),degree of spinal cord injury(complete injury),course of disease(≥6 months),bladder compliance(abnormal),urinary system infection(yes)and detrusor sphincter disorder(yes)were all independent risk factors for NB in patients with spinal cord injury(P<0.05).Probability forecasting model P=1/[1+e-(-6.008+0.791*X1+3.117*X2+1.492*X3+1.270*X4+1.516*X5+2.158*X6)],models to predict the overall accuracy is 80.5%;The prediction accuracy of the model is 71.7%through the cross-verification of 5 fold.Decision tree model showed that the degree of spinal cord injury had the greatest effect on the complication of NB in patients with spinal cord injury,and the information gain was 0.46.ROC results showed that the AUC values of NB predicted by the two models were close(0.873 vs.0.852,Z=0.875,P=0.469).Conclusion The level of spinal cord injury,degree of spinal cord injury,course of disease,bladder compliance,urinary system infection,detrusor sphincter disorder can all predict the risk of NB.The decision tree model constructed in this study can effectively predict the risk probability of NB in patients with spinal cord injury,and medical staff can make targeted plans according to the above factors to reduce the risk of NB.

Objective:To investigate the effect and mechanism of Huanglian Jiedu Decoction(HLJDD)on platelet-neutrophil crosstalk in inflammatory response.Methods:The rat model of inflammatory reaction was induced by lipopolysaccharide(LPS),and HLJDD was used to intervene LPS rats.Proinflammatory factors and platelet-neutrophil cross-talk were detected.Immunofluorescence and HE staining were used to observe the platelet-neutrophil adhesion rate in lung tissue and lung histopathology.Transcriptomics was used to explore the potential signaling pathways and targets of HLJDD in platelet-neutrophil crosstalk and verified them.Results:Com-pared with the control group,the white blood cell count,platelet count,plasma TNF-α,IL-1β,SLEP,sC5b-9 and ICAM-1 levels in the model group were significantly increased,and the positive expression rates of CD62p,MPO and CD61+CD62p+MPO coincidence in the lung tissue of the model group were also significantly increased(P<0.001 or P<0.05).The inflammatory injury was severe in the model group.Compared with the model group,the white blood cell count,plasma levels of TNF-α,IL-1β,SLEP,sC5b-9 and ICAM-1 in the HLJDD group were decreased(P<0.001 or P<0.05),the positive expression rates of CD62p and MPO and the coincident posi-tive expression rates of CD61+CD62p+MPO in the lung tissue of the HLJDD group were decreased(P<0.05),and LPS-induced lung tis-sue injury was alleviated.Transcriptomics results showed that high-dose HLJDD could down-regulate differential genes on oxidative phosphorylation pathways.Conclusion:HLJDD ameliorates LPS-induced inflammatory response and reduces platelet-neutrophil cross-talk,which may be related to the down-regulation of oxidative phosphorylation.

Objective:To investigate the influencing factors and prognosis of early recurrence after gastrectomy for gastric cancer.Methods:The retrospective cohort study was conducted. The clinicopathological data of 2 078 patients who underwent gastrectomy for gastric cancer at six medical centers across China, including Fudan University Shanghai Cancer Center et al, between January 2012 and June 2023 were collected. There were 1 449 males and 629 females, aged (59±11) years. Patients were classified as early recurrence and late recurrence based on the time of post-operative recurrence. Observation indicators: (1) comparison of clinicopathological characteristics between gastric cancer patients with different recurrence types; (2) recurrence and metastasis of tumor; (3) survival of patients after postoperative recurrence of gastric cancer; (4) analysis of influencing factors for early recurrence after gastrectomy for gastric cancer. Comparison of measurement data with normal distribution between groups was conducted using the independent sample t test. Comparison of measurement data with skewed distribution between groups was conducted using the Mann-Whitney U test. Comparison of count data between groups was conducted using the chi-square test. Comparison of ordinal data between groups was conducted using the rank sum test. Multivariate analysis was conducted using the Logistic regression model. Kaplan-Meier method was used to calculate survival rate and plot survival curve, and Log-rank test was used for survival analysis. Results:(1) Comparison of clinicopathological characteristics between gastric cancer patients with different recurrence types. Among the 2 078 patients, 1 452 cases had early recurrence and 626 cases had late recurrence. There were significant differences in preoperative carcinoembryonic antigen, preoperative CA19-9, preoperative CA72-4, preoperative albumin, tumor diameter, neoadjuvant therapy, R 0 resection, combined organ resection, scope of gastric resection, nerve and vessel infiltration, degree of tumor differentiation, pathological N staging, pathological TNM staging between early and late recurrence patients ( P<0.05). (2) Recurrence and metastasis of tumor. Among the 2 078 patients, 200 cases had local recurrence, 1 213 cases had hematogenous metastases, 392 cases had distant lymph node metastases, and 731 cases had peritoneal metastases. Among the 1 452 early recurrence patients, 142 cases had local recurrence, 834 cases had hematogenous metastases, 289 cases had distant lymph node metastases, and 507 cases had peritoneal metastases. Among the 626 late recurrence patients, 58 cases had local recurrence, 379 cases had hematogenous metastases, 103 cases had distant lymph node metastases, and 224 cases had peritoneal metastases. One patient may have multiple forms of recurrence and metastasis. There was no significant difference in the above indica-tors between early and late recurrence patients ( χ2=0.13, 1.74, 3.40, 0.14, P>0.05). (3) Survival of patients after postoperative recurrence of gastric cancer. All 2 078 patients were followed up until death after recurrence, with a follow-up time of 31(range, 9?147)months. The 1-, 2-, 3-, and 5-year overall survival rates after recurrence were 33.5%, 17.2%, 10.1%, and 3.3% in early recurrence patients, versus 44.2%, 21.6%, 12.8%, and 5.8% in late recurrence patients, respectively, showing a significant difference in overall survival after recurrence between the two groups ( hazard ratio=0.84, 95% confidence interval as 0.76?0.92, P<0.05). (4) Analysis of influencing factors for early recurrence after gastrectomy for gastric cancer. Results of multivariate analysis showed that combined organ resection, total gastrectomy, pathological TNM staging as stage Ⅲ were independent risk factors for early recurrence after gastrectomy for gastric cancer ( odds ratio=1.31, 1.32, 1.34, 95% confidence interval as 1.01?1.70, 1.06?1.65, 1.05?1.71, P<0.05) and normal preoperative tumor markers, neoadjuvant therapy, R 0 resection were independent protective factors for early recurrence ( odds ratio=0.61, 0.50, 0.38, 95% confidence interval as 0.49?0.76, 0.35?0.72, 0.25?0.58, P<0.05). Conclusions:Compared with patients with late recurrence after gastric cancer surgery, patients with early recurrence have a poor prognosis, in which liver metastases is more common. Combine organ resection, total gastrectomy, pathological TNM staging as stage Ⅲ are independent risk factors for early recurrence, and normal preoperative tumor markers, neoadjuvant therapy, R 0 resection are independent protective factors for early recurrence after gastrectomy for gastric cancer.

Objective To analyze the risk factors of neurogenic bladder dysfunction(NB)in patients with spinal cord injury,and establish a risk prediction model of NB in patients with spinal cord injury by decision tree algorithm.Method Clinical data of 176 patients with spinal cord injury admitted from April 2022 to July 2024 were retrospectively analyzed.Patients with spinal cord injury were divided into disorder group and non-disorder group according to whether they were complicated by NB.Multivariate Logistic regression analysis was used to screen the risk factors of NB.Modeler software was used to construct the decision tree model of spinal cord injury patients with concurrent NB,and the 5-fold cross-validation method was used to internally verify the model,and the prediction efficiency of the model was compared.Results Among 176 patients with spinal cord injury,42 patients had concurrent NB,the incidence of NB was 23.86%.Logistic regression analysis showed that the level of spinal cord injury(T10—L2),degree of spinal cord injury(complete injury),course of disease(≥6 months),bladder compliance(abnormal),urinary system infection(yes)and detrusor sphincter disorder(yes)were all independent risk factors for NB in patients with spinal cord injury(P<0.05).Probability forecasting model P=1/[1+e-(-6.008+0.791*X1+3.117*X2+1.492*X3+1.270*X4+1.516*X5+2.158*X6)],models to predict the overall accuracy is 80.5%;The prediction accuracy of the model is 71.7%through the cross-verification of 5 fold.Decision tree model showed that the degree of spinal cord injury had the greatest effect on the complication of NB in patients with spinal cord injury,and the information gain was 0.46.ROC results showed that the AUC values of NB predicted by the two models were close(0.873 vs.0.852,Z=0.875,P=0.469).Conclusion The level of spinal cord injury,degree of spinal cord injury,course of disease,bladder compliance,urinary system infection,detrusor sphincter disorder can all predict the risk of NB.The decision tree model constructed in this study can effectively predict the risk probability of NB in patients with spinal cord injury,and medical staff can make targeted plans according to the above factors to reduce the risk of NB.

Objective:To explore the optimal age cutoff for diagnosis and the prognosis of early-onset gastric cancer in young patients.Methods:Clinicopathological data of patients with gastric adenocarcinoma aged ≤45 years who had undergone radical gastrectomy in the Department of Gastric Surgery, Fudan University Shanghai Cancer Center from January 2013 to December 2018 were retrospectively collected. Patients with distant metastases, other malignant tumors, combined organ resection, gastric stump cancer, positive margin, and incomplete clinical or follow-up data were excluded. X-tile software analysis of the actual overall survival of the collected cases yielded an optimal cut-off of 32 years. Accordingly, the enrolled cases were divided into an early-onset young group (age ≤32 years) and young adult group (age >32 years). Clinicopathological characteristics, long-term survival, and postoperative recurrence were compared between the two groups. Univariate and multivariate analyses were performed using the Cox proportional hazards model to identify the factors affecting the prognosis of young patients with gastric cancer.Results:The study cohort comprised 462 patients, including 256 (55.4%) women, 419 (90.7%) with middle and lower gastric cancers, and 343 (74.2%) with poorly differentiated tumors. There were 101 patients in the early-onset young group and 361 in the young adult group. These groups did not differ significantly in terms of sex, body mass index, tumor location, tumor size, surgical procedure, neurovascular invasion, or tumor stage (all P>0.05). The proportion of patients with poorly differentiated tumors in the early-onset young group was significantly higher than that in the young adult group (89.1%[90/101] vs. 70.1%[253/361], χ 2=15.26, P<0.001). All study patients completed 5 years of follow-up, the median duration of which was 101 months (61-133 months). Death or tumor recurrence occurred in 151 patients (32.7%), in 118 of whom the sites of recurrence and metastasis could be identified, 38 in the early-onset young group and 80 in the young adult group. Fifty-five (46.6%) patients developed peritoneal metastases and 40 (33.9%) hematogenous metastases. In the early-onset young group, 20 patients developed peritoneal metastases, 11 hematogenous metastases, five distant lymph node metastases, and two local recurrence. In the young adult group, 35 patients developed peritoneal metastases, 29 hematogenous metastases, six local recurrences, and 10 distant lymph node metastases. The 5-year overall survival and disease-free survival rates were significantly higher in the young adult group than in the early-onset young group (73.7% vs. 57.4%, P=0.002 and 70.6% vs. 55.4%, P=0.004, respectively). Cox multivariate analysis showed that age >32 years (HR=0.63, 95%CI: 0.43-0.90, P=0.012) was an independent protective factor for overall survival, whereas later N stage (HR=1.67, 95%CI:1.09-2.57, P=0.018) was an independent risk factor for overall survival after surgery ( P<0.05). Age >32 years (HR=0.60, 95%CI: 0.41-0.86, P=0.006) was also an independent protective factor for disease-free survival, whereas later N stage was an independent risk factor (HR=1.69, 95%CI: 1.08-2.64, P=0.021). Conclusion:Young patients with early-onset gastric cancer aged ≤32 years have worse tumor differentiation and prognosis.

The rapid development of immunotherapy has changed the treatment pattern of gastric cancer surgery, constantly advancing from the battlefield of advanced gastric cancer treatment to neoadjuvant therapy. The combination of immunotherapy and chemotherapy has become a new trend in the treatment of locally advanced gastric cancer. This change has prompted us to re-examine the concept of traditional radical surgery for gastric cancer, especially for lymph node dissection, it presents new challenges. As the core site of immune response, lymph node dissection strategy has become one of the key factors affecting the overall efficacy of gastric cancer, and it urgently needs to be re optimized and evaluated in the wave of immunotherapy. Thus, a more precise and personalized new paradigm for radical gastric cancer surgery can be established, ultimately achieving multiple improvements in short-term and long-term efficacy, as well as quality of life.